lamivudine / Generic mfg. - LARVOL DELTA

ATYPICAL IGA NEPHROPATHY UNMASKED BY IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A HIV PATIENT (ISN-WCN 2026) - "However, IRIS leading to the unmasking of glomerular diseases is rarely reported.Methods A 42-year-old woman diagnosed with HIV presented with nausea and vomiting for 2 weeks, two months after starting highly active antiretroviral therapy (HAART) containing tenofovir disoproxil fumarate (TDF) 300 mg, lamivudine 300mg, and dolutegravir 50 mg...DIF studies showed mesangial IgA (3+), C3 (1+), and kappa (3+) staining and lambda (1+).Download: Download high-res image (868KB)Download: Download full-size imageResults She was treated with IV methylprednisolone 500 mg for 3 doses, followed by oral prednisolone at 0.5 mg/kg body weight. HAART was modified to an abacavir-based regimen...To conclude, this case emphasizes the need for clinicians to be aware of the diverse renal manifestations of IRIS in the setting of HIV. It also underscores the need for vigilance after initiating HAART."

Clinical • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammatory Arthritis • Monoclonal Gammopathy • Renal Disease • CD4

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy. (PubMed, HIV Med) - "In this cross-sectional assessment, no evidence of HBV reactivation was detected in people living with HIV with isolated anti-HBc receiving TFV-sparing dual ART, including regimens without direct anti-HBV activity."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

NEURODEGENERATION AND TRANSPOSABLE ELEMENT–DRIVEN IMMUNE RESPONSES IN C9ORF72-ALS/FTD (ADPD 2026) - "This study provides the first demonstration that the RTE–RNA::DNA hybrid–STING axis is aberrantly activated in C9-ALS/FTD, linking retrotransposon dysregulation to disease-relevant innate immune signaling. By showing that RNA::DNA hybrid accumulation can be reduced with lamivudine, we highlight a translatable therapeutic entry point targeting this pathway in C9-ALS/FTD and related dementias."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia

Late-onset de novo HBV infection with lamivudine resistance in a liver transplant recipient from an anti-HBc–positive donor (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Infectious Disease • Transplantation

Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine? (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Real-World Experience of 25 Years of Lamivudine Therapy: Highlighting Favorable Long-Term Outcomes in Chronic Hepatitis B (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B (EASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Negative influence of age and low baseline CD4 on T helper cell recovery among HIV-infected individuals with fixed-dose combination of tenofovir disoproxil, lamivudine and dolutegravir. (PubMed, Front Public Health) - "This study evaluated DIR in HIV-positive patients receiving a first-line regimen of tenofovir disoproxil fumarate, lamivudine and dolutegravir (TLD) at the ART Centre, Saveetha Medical College and Hospital, Chennai, India. Lower baseline CD4 was observed to be a key predictor of DIR. These findings underscore the need for early ART initiation, targeted adherence support, and counselling to optimize outcomes and progress toward the UNAIDS 95 target."

Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4

Lightning strikes thrice: a case report of triple positive ANCA associated vasculitis (UKKW 2026) - "She had taken short courses of traditional Chinese medicine herbal remedies, ibuprofen, naproxen, and omeprazole for treatment of her joint stiffness...She was treated for Anca-Associated Vasculitis (AAV) with rituximab and cyclophosphamide: the prednisolone was later converted to avacopan. Hepatitis B core antibody was positive so she was also started on lamivudine prophylaxis...Few cases have been described where other autoantibodies are also positive. Patient’s consent: the patient has given verbal documented consent and written consent for publication."

Case report • Clinical • ANCA Vasculitis • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

From Genome Diversity to Inferred Functional Constraints: An Integrated Evolutionary Analysis of Hepatitis B Virus Genotype F. (PubMed, Int J Mol Sci) - "Some mutations in the major hydrophilic region (MHR) were significantly detected, whereas RT drug resistance mutations were rare and followed canonical lamivudine-associated pathways. Collectively, these findings highlight the balance between deep evolutionary conservation and localized adaptive flexibility in shaping the HBV genotype F and provide a genotype-specific framework for interpreting viral fitness, immune interactions, and antiviral resistance."

Journal • Hepatitis B • Infectious Disease • Inflammation

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa. (PubMed, Clin Infect Dis) - "Among PLHIV in South Africa we found no increased MACE with TLD."

Adverse events • Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

D3 (Penta21): DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (clinicaltrials.gov) - P2/3 | N=386 | Active, not recruiting | Sponsor: PENTA Foundation | Trial completion date: Sep 2025 ➔ Sep 2026

Head-to-Head • Trial completion date • Human Immunodeficiency Virus • Infectious Disease

Oral Lamivudine for Extended HIV Postnatal Prophylaxis. (PubMed, Paediatr Drugs) - "The antiretroviral drugs most commonly studied as ePNP, either alone or in combination, are lamivudine, nevirapine, lopinavir/ritonavir and zidovudine. Guided by maternal HIV viral load, ePNP may be particularly indicated, as it could ensure that the prophylaxis provides the greatest benefit/risk to children at highest risk. Long-acting injectable antiretroviral drugs and broadly neutralising antibodies (bNAbs) have yet to be fully evaluated in neonates, infants and children; however, they may offer new alternatives in the future."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Use of Hepatitis B Virus (HBV)-Positive Organs (HBsAg+ or NAT+) for Heart Transplant (ISHLT 2026) - "Prophylaxis strategies included antiviral agents (entecavir and lamivudine) along with hepatitis B immune globulin (HBIG)...One of the five did seroconvert (new HBcAb+) after transplant despite prophylaxis, although the clinical significance of this is not clear given the patient never had significant signs or symptoms of infection and remains HBsAb+ and HBsAg-/NAT-.Conclusion This case series supports the feasibility of using HBV-positive donors for heart transplant with close monitoring. Further research is needed to determine appropriate prophylaxis strategies and assess long-term outcomes."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

LAMIFERON: A single-center study to assess the effect of lamivudine (3TC) on cognitive impairment (alterations in thinking, learning, memory...) by the analysis of the plasma of patients with Mild Cognitive Impairment (MCI) (clinicaltrialsregister.eu) - P1/2 | N=25 | Completed | Sponsor: Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia | Active, not recruiting ➔ Completed

Biomarker • Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial. (PubMed, BMJ Open) - P3 | "Participants will be randomised in a 1:1 ratio to receive either DOR 100 mg once daily in combination with tenofovir disoproxil fumarate (TDF) (300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus either emtricitabine (FTC) (200 mg daily) or 3TC (300 mg daily). Results will also be communicated to policymakers, healthcare professionals, community stakeholders and study participants through appropriate dissemination activities, including policy briefs, stakeholder meetings and lay summaries on dedicated and easily accessible platforms. NCT06203132; EU-CT, 2023-508626-10-00."

Clinical protocol • Head-to-Head • Journal • P3 data • Cardiovascular • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders

Design of ZIF-L-based boronate affinity molecularly imprinted material and its application in the detection of ribavirin in environmental water (PubMed, Se Pu) - "In mixed solutions of RBV and three interfering substances （lamivudine，uridine，inosine） with mass concentration ratios of 1∶1 and 1∶10， the adsorption capacity of RBV by ZIF@B-MIPs remained high. It holds potential for applications in the fields of human health and environmental protection. This technology offers a new strategy for the rapid detection of trace antiviral drugs in environmental samples."

Journal • Infectious Disease

Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "Oral lamivudine or entecavir and interferon-α (IFN-α) or pegylated interferon-α (PEG-IFN-α) were administered to the NA and NA+IFN groups... The antiviral efficacy of the NA+IFN combination therapy group was superior to that of the NA monotherapy group at 48 weeks in children with CHB 4-6 years old. However, there was no statistically significant difference in the efficacy of the two antiviral regimens among young children 1-3 years old, hinting that NA therapy may be a priority for young children."

Clinical • Journal • Monotherapy • Hepatitis B • Infectious Disease • Inflammation • IFNA1

HIV-1 drug resistance and genetic clustering among ART-treated individuals with virologic failure in Aksu, China. (PubMed, Front Microbiol) - "The most common DRMs were K103N/S (60.7%), M184V/I (27.3%), G190A/E/S (11.3%), and E138A/K/Q/G (10.8%), conferring high-level resistance mainly to lamivudine (3TC), efavirenz (EFV), and nevirapine (NVP)...The clustering of DRMs underscores the importance of molecular surveillance for guiding targeted interventions. These findings support accelerating access to effective second-line regimens, strengthening pretreatment resistance surveillance, and prioritizing adherence support among central individuals with high viral loads."

Journal • Human Immunodeficiency Virus • Infectious Disease

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous-venous extracorporeal membrane oxygenation (VV-ECMO): A case report. (PubMed, Br J Clin Pharmacol) - "Our findings support considerations for pre-emptive dose intensification for dolutegravir and tenofovir in patients with human immunodeficiency virus (HIV)/AIDS undergoing ECMO to ensure adequate antiretroviral treatment. The case is illustrative for the clinical pharmacological challenges faced in critically ill patients with HIV/AIDS undergoing ECMO and provides guidance for future cases."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pneumonia • Respiratory Diseases

Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release. (PubMed, Nanoscale Adv) - "In this study, we demonstrate a cryopreservable LNP formulation incorporating a hydrophobically modified bis-prodrug of lamivudine...This work highlights the opportunity of a prodrug-based strategy to formulate water-soluble APIs into stable, freeze-dried LNPs, enabling controlled, enzyme-responsive release. These findings offer insight into how surfactant composition influences freeze-drying compatibility and provide a platform for the development of LNP systems for small molecule delivery."

Journal

Triterpenoids CDDO and CDDO-EA Inhibit the Replication of Hepatitis B Virus by Modulating Nucleocapsid Assembly. (PubMed, Int J Mol Sci) - "Finally, a synergistic effect was observed between CDDO-EA and lamivudine in reducing intracellular and extracellular HBV DNA levels. Our findings indicate that triterpenoids CDDO and CDDO-EA are new mechanistically type of HBV capsid assembly modulators and warranted for further development as lead compounds against HBV."

Journal • Hepatitis B • Infectious Disease • Inflammation

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12... (PubMed, Contemp Clin Trials) - P3 | "LATA is the first trial comparing the efficacy, safety and acceptability of LAI CAB/RPV to oral ART in AHIV, enrolled in Sub-Saharan Africa, using a programmatic approach to viral load testing."

Head-to-Head • HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease